Stock Comparison

ABBV vs AMIX

AbbVie Inc vs Autonomix Medical Inc

The Verdict

AMIX takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

AMIX

Autonomix Medical Inc

5.3

out of 10

Proceed with Caution

Head-to-Head

$381.1B

Market Cap

$4M

104.8

P/E Ratio

N/A

5.8%

Profit Margin

N/A

95.6%

Return on Equity

-228.8%

20.2

Debt-to-Equity

N/A

Moderate

Overall Risk

Aggressive

0.1

DVR Score

5.3

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

AMIX5.3/10

Autonomix Medical Inc. (AMIX) remains an extremely speculative micro-cap with immense 10x growth potential if its proprietary nerve signal analysis platform achieves clinical and regulatory success. The intrinsic market opportunity in nerve-related conditions and the potential competitive advantage are strong. Recent clinical progress, evidenced by abstract acceptance for Digestive Disease Week 20...

Full AMIX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.